New funding: Curi Bio raised $6 million to further develop its human stem cell-based platforms for drug discovery. Dynamk Capital led the Series A round.
Company background: The Seattle startup, previously known as NanoSurface Biomedical, aims to provide drug developers with human-relevant cells, systems, and data to speed up the drug discovery process in the cardiac, skeletal muscle, and neuromuscular fields. Curi acquired Silene Biotech in 2019.
Founders: Elliot Fisher, chief business officer, started NanoSurface with his former research advisor at the University of Washington, Deok-Ho Kim, who is CEO.